Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00763750 · ClinicalTrials.gov registry record · Phase 2
PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
A Phase 2 study of Brain Tumor, sponsored by howard safran.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00763750 is a Phase 2 study of Brain Tumor that has completed, run by howard safran. The registered enrollment target is 25 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00763750, a Phase 2 study of Brain Tumor, has completed, sponsored by howard safran.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.
Conditions Studied
Interventions
- DRUG PPX +TMZ+XRT
Study Locations (1)
Rhode Island
- Lifespan Hospitals - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00763750
The ClinicalTrials.gov registry entry for NCT00763750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (91% lower). The listed sponsor is howard safran, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which PPX +TMZ+XRT is the first listed.
NCT00763750 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00763750 about?
NCT00763750 is a clinical study titled "PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors". The purpose of this study is to determine the antitumor activity of PPX in combination with temozolomide and radiation for patients with newly diagnosed brain tumors.
What is the current status of trial NCT00763750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-10. Estimated completion is 2012-07.
What conditions does trial NCT00763750 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT00763750?
The interventions under investigation include: PPX +TMZ+XRT (DRUG).
Who is sponsoring clinical trial NCT00763750?
This trial is sponsored by howard safran, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00763750 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
RECRUITING · Phase 2
-
Quantitative Assessment of Radiation-induced Neuroinflammation - A Proof of Principle Study
ACTIVE NOT RECRUITING · Phase 2
-
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
ACTIVE NOT RECRUITING · Phase 2
-
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.